The trusted source for
healthcare information and
Stakeholders group gives advice, support
The Stakeholders Association of the Global Alliance for TB Drug Development, a private-public partnership intended to speed the development of new TB drugs, has elected as its new president Lee B. Reichman, MD, MPH, director of the National TB Center at the New Jersey Medical School in Newark.
Maria Freire, PhD, CEO of the TB Alliance, says Reichman’s election is "thrilling." The Stakeholders Association "is essential to our effort to educate opinion makers around the world about the threat of tuberculosis," she adds. As the group’s president, Reichman will sit on the alliance’s board, replacing outgoing stakeholders’ president James Orbinsky, MD, former president of Doctors Without Borders.
"For years I’ve been a broken record about the need for new TB drugs," says Reichman. "So formally heading the Stakeholders Association brings my work full circle. For years, many of us knew the only way a new TB drug could be developed was through an innovative public-private partnership like the TB Alliance. It will be rewarding to have an inside seat at an institution I’ve spent years clamoring for."
The Stakeholders Association consists of 122 members who meet at least once a year. The group was formed in February 2000, when TB experts and other interested parties gathered in Capetown, South Africa, to affirm the creation of the alliance. That original group included 120 members; now, two more members have been added, including the Filipino Coalition Against TB, or filCAT; and the India-based National Institute of Pharmaceutical Education and Research, or NIPER.